Cann Group Valuation

Is CAN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CAN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CAN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CAN's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CAN?

Key metric: As CAN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CAN. This is calculated by dividing CAN's market cap by their current revenue.
What is CAN's PS Ratio?
PS Ratio	1.1x
Sales	AU$18.36m
Market Cap	AU$21.57m

CAN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5x
Enterprise Value/EBITDA	-6.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does CAN's PS Ratio compare to its peers?

The above table shows the PS ratio for CAN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.1x
AGH Althea Group Holdings	0.6x	n/a	AU$19.3m
NYR Nyrada	6.5x	n/a	AU$21.0m
IVX Invion	3.9x	n/a	AU$14.3m
RNO Rhinomed	1.4x	n/a	AU$11.5m
CAN Cann Group	1.2x	n/a	AU$21.6m

Price-To-Sales vs Peers: CAN is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (3.1x).

Price to Sales Ratio vs Industry

How does CAN's PS Ratio compare vs other companies in the AU Pharmaceuticals Industry?

16 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	4.9x	35.5%
CAN Cann Group	1.2x	n/a	US$14.02m
MYX Mayne Pharma Group	0.9x	11.3%	US$236.25m
PBP Probiotec	1.1x	6.7%	US$160.13m

16 Companies		Estimated Growth	Market Cap
Industry Avg.	4.9x	47.8%
CAN Cann Group	1.2x	n/a	US$14.02m

No more companies

Price-To-Sales vs Industry: CAN is good value based on its Price-To-Sales Ratio (1.2x) compared to the Australian Pharmaceuticals industry average (4.9x).

Price to Sales Ratio vs Fair Ratio

What is CAN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CAN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CAN's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Little Green Pharma

AU$39.2m

Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

LGP

AU$0.14

10.2%

Medical Developments International

AU$47.3m

Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.

MVP

AU$0.42

-5.6%

-46.8%

AVITA Medical

US$349.9m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.93

2.3%

20.4%